

# EFFICACY AND SAFETY OF DUPILUMAB MAINTAINED IN ADULTS $\geq 60$ YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF POOLED DATA FROM FOUR RANDOMIZED CLINICAL TRIALS

Jonathan I. Silverberg · Charles W. Lynde · Katrina Abuabara · Cataldo Patrino · Anna De Benedetto · Haixin Zhang · Ryan B. Thomas · Gaëlle Bégo-Le-Bagousse · Faisal A. Khokhar · Jignesh Vakil · Ainara Rodríguez Marco · Noah A. Levit

American Journal of Clinical Dermatology

4 randomized, placebo-controlled clinical trials of dupilumab



2444 patients in total

183 patients



$\geq 60$  years of age

## WEEK 16 EFFICACY DATA

Adults  $\geq 60$  years of age

### IGA 0/1

clear/almost clear skin  
Investigator's Global Assessment

44%

7%

Dupilumab  
300 mg q2w<sup>a</sup>

Placebo

### EASI-75

75% improvement in  
Eczema Area and Severity Index

63%

14%

Dupilumab  
300 mg q2w

Placebo

### ITCH

Patients with  $\geq 4$ -point improvement  
in Peak Pruritus NRS

44%

26%

Dupilumab  
300 mg q2w

Placebo

### DLQI

Patients with  $\geq 4$ -point improvement  
in Dermatology Life Quality Index

86%

38%

Dupilumab  
300 mg q2w

Placebo

<sup>a</sup>Every 2 weeks.

## WEEK 16 SAFETY DATA

Adults  $\geq 60$  years of age

32 patients

337.51 nP/100PY<sup>b</sup>

Dupilumab  
300 mg q2w

Patients with at least 1 adverse event

40 patients

577.93 nP/100PY

Placebo

<sup>b</sup>Number of patients per 100 patient-years.

## CONCLUSION

Dupilumab improved atopic dermatitis signs, symptoms, and quality of life in patients aged 60 years and older, and has an acceptable safety profile. These results are consistent with those in patients younger than 60 years of age.

